2015
DOI: 10.1016/j.lungcan.2015.04.015
|View full text |Cite
|
Sign up to set email alerts
|

A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511)

Abstract: Objectives Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. Materials and Methods The study employed the 3+3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75mg/m2 on D1) and E (100mg/m2 on D1-3) in a 21-day cycle. The starting dose of V was 60mg (bid D1-7) with plan to escala… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
35
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
8
2

Relationship

3
7

Authors

Journals

citations
Cited by 49 publications
(35 citation statements)
references
References 21 publications
0
35
0
Order By: Relevance
“…Although chemotherapies have strong effects on some kinds of tumors, such as small cell lung cancer [5] and lymphomas [6], the overall response rate is less than satisfactory for many tumors [7]. Furthermore, drug resistance, tumor recurrence, and metastasis make tumor treatment more difficult.…”
Section: Tams Lead To a Poor Clinical Prognosis And Promote Progrementioning
confidence: 99%
“…Although chemotherapies have strong effects on some kinds of tumors, such as small cell lung cancer [5] and lymphomas [6], the overall response rate is less than satisfactory for many tumors [7]. Furthermore, drug resistance, tumor recurrence, and metastasis make tumor treatment more difficult.…”
Section: Tams Lead To a Poor Clinical Prognosis And Promote Progrementioning
confidence: 99%
“…This demonstrated the ability to safely deliver the combination of veliparib for 7 days of the 21 day cycle and resulted in an ORR of 71% (5/7 patients, 1 complete response (CR)). Although comparable to historical responses from chemotherapy alone the result proved that a PARP inhibitor could be tolerated in combination with chemotherapy [51]. The subsequent ECOG-ACRIN 2511 study (NCT01642251) of veliparib added to cisplatin and etoposide versus chemotherapy alone in the same 1st line setting was recently reported in abstract form [52].…”
Section: Veliparibmentioning
confidence: 81%
“…A randomized, Phase 2, double-blind Small cell lung cancer Trial of Olaparib as Maintenance Program (or “STOMP”) which compares PARP inhibition to placebo following first-line chemotherapy (Cancer Research UK, trial number CRUK/10/037) has recently closed to recruitment and results are awaited 106 . A phase I trial combining veliparib with cisplatin and etoposide (ECOG-ACRIN E2518) 107 successfully completed and is now active as a randomized phase II trial. The newer PARP inhibitor talazoparib kills SCLC cells more efficiently than the older PARP inhibitor olaparib 43 and had single agent activity in SCLC in a recently completed Phase 1 trial 42 .…”
Section: New Sclc Targets and Drugsmentioning
confidence: 99%